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1. Correction of misprints and minor editorial changes 
 
This Addendum 1 has been created to list minor changes made in SAP Version 1.1 due to misprints 
and minor editorial changes found during the statistical analysis. 
 
Applicable section and 
description 
Before Changes in the addendum 
5. DEMOGRAPHIC AND 
BASELINE 
CHARACTERISTICS 
Baseline data 
Correction of misprints 
 Nominal variables 
FG score (FG=3 or FG>=4), 
urine test (urinary protein, 
urinary glucose), pregnancy 
test (results), ECG evaluation, 
anti-ganglioside antibody 
 Ordinal variables 
FG, R-ODS score, ONLS 
score, MMT scale score (left 
and right) 
 Nominal variables 
FG score (FG=3 or FG>=4), 
pregnancy test (results), ECG 
evaluation, anti-ganglioside 
antibody 
 Ordinal variables 
FG, R-ODS score, ONLS 
score, MMT scale score (left 
and right), urine test (urinary 
protein, urinary glucose, 
hematuria) 
6.2.1.Secondary Efficacy 
Endpoints 
(1) and (2) 
Addition of detailed 
description to make it clearly 
understandable 
 
 
 
The proportion at each point 
and its 95% confidence 
interval, as well as the 
difference will be presented to 
compare the treatment groups. 
When generalized linear 
mixed model (GLMM) is not 
applicable, Fisher’s exact test 
will be performed.  
 
 
The proportion at each point 
and its 95% confidence 
interval, as well as the odds 
ratios (using placebo as the 
reference category) will be 
presented to compare the 
treatment groups. When the 
generalized linear mixed 
model (GLMM) is not 
applicable, Fisher’s exact test 
will be performed.  
7.2. Analysis Plan for Clinical 
Assessment Values and Vital 
Signs  
 
Deletion of misprints 
 
 
Each measurement parameter 
will be calculated for 
descriptive statistic values (n, 
mean, standard deviation, 
minimum, maximum, and 
median) and interval 
estimation for the parent 
Each measurement parameter 
will be calculated for 
descriptive statistic values (n, 
mean, standard deviation, 
minimum, maximum, and 
median). For urinalysis 
parameters, the number and 
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population. For urinalysis 
parameters, the number and 
the incidence rate will be 
calculated by two-sided 95% 
CI. 
the incidence rate will be 
calculated. 
 
 
